ETFsiBoxx EUR Liquid High Yield Index TRI
Amundi

Amundi Core EUR High Yield Bond UCITS ETF Acc

LU2970735911 EUFUNDAccumulatingPhysical, full replicationLuxembourgNot PEA-eligible
Last close · EUR
10.26EUR
0.00% · +€0.00
Published closes: 5 Nov 2026 - 6 Nov 2026
6 Nov 2026, close
LU2970735911Base
Fund charges
0.15%Total expense ratio (TER)
Fund size
€550.1Mall share classes
Return 1Y
+0.9%
Sharpe 3Y
Not published
Volatility 1Y
3.2%annualised
Holdings
652Fund holdings

Performance

Compare
  • LU2970735911+0.9%
  • Price, EUR

Returns

Returns1M3M6MYTD1Y3Y5Y
LU29707359110.0%-1.3%-0.6%0.0%+0.9%--
MSCI World-3.4%-0.6%+6.5%+13.9%+15.5%+65.4%+64.7%
Gap to MSCI World+3.4%-0.7%-7.1%-13.9%-14.6%--

Risk and return

Sharpe ratio · 1Y
-0.28
Below MSCI World · 1.40
Return p.a.
+1.1%
Volatility
3.2%
Max loss
-3.2%Oct 2026

Sharpe vs indices

MSCI World
1.40
S&P 500
1.29
STOXX Europe 600
1.12
MSCI Emerging Markets IMI
0.77
CAC 40
0.32
LU2970735911
-0.28
Method

Weekly EUR returns from adjusted closes. Sharpe is the annualised excess return over the euro overnight rate (Xtrackers II EUR Overnight Rate Swap UCITS ETF 1C) divided by its volatility. Max loss uses daily closes.

Top holdings

Top 10
3.9%
Holdings
652
As of
Fund holdings
  1. 1COREWEAVE INC 8.5% Jul32XS33331392880.45%
  2. 2ASSEMBLIN CAV FRN Oct33XS34899418260.42%
  3. 3FIBERCOP SPA 5.375% Apr31XS33387859370.42%
  4. 4GRIFOLS SA 3.875% Oct28XS23930018910.39%
  5. 5UNITED GROUP FRN Jan33XS32748279330.39%
  6. 6ZF EUROPE FIN 7% Jun30 EMTNXS30916601940.37%
  7. 7VMED O2 UK FI 5.625% Apr32XS27966003070.36%
  8. 8OPALBD 5 1/2 03/31/32XS30376433040.36%
  9. 9BIDCO 1/2/3/G 6.5% Jun33XS33676133640.36%
  10. 10ORGANON & CO/ 2.875% Apr28XS23322507080.36%

Countries

Classified 99.5%
Largest
19.1%France
Top 3
48.6%
Effective number
9.01 / HHI

Market cap

Weight vs holdings

3.9%of the fund sits in the top 10 holdings
  • Holdings 1-10
  • Holdings 11-50
  • Holdings 51-200
  • Holdings 201+

Size split

Not published

Compare ETFs in Copio.

ETF comparison in the Copio app, showing costs and returns with illustrative data.

Factual research, without a suitability score or investment recommendation. Past relationships can change.